No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
GRAIL to Present New Data on Galleri and Its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
CCORF Initiates Grail(GRAL.US) With Buy Rating, Announces Target Price $32
This Cancer Test Could Become Routine -- and a Big Seller, Says Analyst -- Barrons.com
Canaccord Genuity Initiates Coverage On GRAIL With Buy Rating, Announces Price Target of $32
GRAIL, Inc. (GRAL): A Bull Case Theory